Treatment for telangiectasias and reticular veins
Appendices
Appendix 1. Glossary
| acne vulgaris | skin disease caused by overactivity of sebaceous glands |
| ambulatory | people treated out with the hospital setting |
| angiomas | dilatation or new formation of blood vessels |
| arterioles | small branches of an artery |
| atrophic blanche | small smooth ivory‐white areas on the skin with hyperpigmented borders and telangiectasias |
| chromophore | chemical group that absorbs light at a specific frequency |
| dermal | relating to skin and specially to the dermis |
| dorsum | the dorsal part of an organism |
| endothelium | tissue that forms a single layer of cells lining various organs |
| epidermal | nonsensitive layer of the skin |
| erythema | superficial reddening of the skin |
| extravasation | escape of blood from a vessel into the tissues |
| fibrosis | the thickening and scarring of connective tissue |
| hypopigmentation | decreased pigmentation of an area of the skin |
| hyperpigmentation | increased pigmentation of an area of the skin |
| lipodermatosclerosis | chronic fibrosing panniculitis associated with venous insufficiency |
| matting | new telangiectasis after treatment |
| melanin | pigment responsible for determining skin and hair colours |
| microthrombi | small thrombus (blood clot formed in situ within the vascular system) |
| necrosis | death of most or all of the cells in an organ or tissue |
| occlusion | blockage of blood vessel |
| oedema | excess of watery fluid collecting in the tissue of the body |
| osmotic | diffusion of fluid through a semipermeable membrane |
| oxyhaemoglobin | substance formed by the combination of haemoglobin with oxygen |
| periorbital | tissues surrounding or lining the orbit of the eye |
| photocoagulation | coagulation of tissue using a laser or other intense light source |
| photothermolysis | a method of laser skin resurfacing |
| polychromatic | various wavelengths or frequencies |
| recanalisation | process of restoring flow of the blood vessels |
| subcutaneous | situated or applied under the skin |
| subdermal | situated or lying under the skin |
| thermocoagulation | coagulation of tissue with high‐frequency currents |
| thermosclerosis | coagulation of blood vessels for heat |
| thrombosis | local coagulation or clotting of the blood in a part of circulatory system |
| vascular | relating to blood vessels |
| venous | relating to a vein |
| venules | very small veins |
| vesicles | small fluid‐filled bladders, sacs, or cysts |
Appendix 2. CENTRAL search strategy
| #1 | MESH DESCRIPTOR Telangiectasis EXPLODE ALL TREES |
| #2 | telangiectas*:TI,AB,KY |
| #3 | microvaric*:TI,AB,KY |
| #4 | (reticular near3 vein*):TI,AB,KY |
| #5 | (reticular near3 varic*):TI,AB,KY |
| #6 | (reticular near3 venous):TI,AB,KY |
| #7 | (thread near3 vein*):TI,AB,KY |
| #8 | (thread near3 varic*):TI,AB,KY |
| #9 | (thread near3 venous):TI,AB,KY |
| #10 | (spider near3 vein*):TI,AB,KY |
| #11 | (spider near3 varic*):TI,AB,KY |
| #12 | (spider near3 venous):TI,AB,KY |
| #13 | angioectasias:TI,AB,KY |
| #14 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 |
Appendix 3. LILACS/BECS search strategy
((MH: "Telangiectasis" OR MH: "Telangiectasia" OR MH: "Telangiectasia" OR "Spider Veins") AND (MH: "Lasers" OR MH: "Rayos Láser" OR MH: "Lasers" OR "Masers" OR E07.632.490$ OR E07.710.520$ OR SP4.011.087.698.384.075.166.027$ OR VS2.006.002.009$ OR MH: "Laser Coagulation" OR MH: "Coagulación con Láser" OR MH: "Fotocoagulação a Laser" OR "Laser Thermocoagulation" OR "Thermocoagulation, Laser" OR E02.520.745.410$ OR E02.594.530$ OR E04.014.520.530$ OR E04.350.750.410$ OR E04.540.630.410$ OR MH: "Low‐Level Light Therapy" OR MH: "Terapia por Luz de Baja Intensidad" OR MH: "Terapia com Luz de Baixa Intensidade" OR "Laser Therapy, Low‐Level" OR "Laser Biostimulation" OR "Laser Irradiation, Low‐Power" OR "LLLT" OR E02.594.540$ OR E02.774.500$ OR MH: "Laser Therapy" OR MH: "Terapia por Láser" OR MH: "Terapia a Laser" OR "Laser Knife" OR "Laser Scalpel" OR "Surgery, Laser" OR "Vaporization, Laser" OR E02.594$ OR E04.014.520$ OR MH: "Lasers, Gas" OR MH: "Láseres de Gas" OR MH: "Lasers de Gás" OR "Argon Ion Lasers" OR "Carbon Dioxide Lasers" OR "CO2 Lasers" OR "Copper Vapor Lasers" OR "Gas Laser" OR "Gas Lasers" OR "Gold Vapor Lasers" OR "Helium Lasers" OR "Helium Neon Gas Lasers" OR "Metal Vapor Lasers" OR "Nitrogen Lasers" OR "Xenon Ion Lasers" OR E07.632.490.367$ OR E07.710.520.367$ OR MH: "Intense Pulsed Light Therapy" OR "Tratamiento de Luz Pulsada Intensa" OR "Terapia de Luz Pulsada Intensa" OR MH: "Sclerotherapy" MH: "Escleroterapia" MH: "Escleroterapia" OR MH: "Sclerosing Solutions" OR MH: "Soluciones Esclerosantes" OR MH: "Soluções Esclerosantes" OR "Injections, Sclerosing" OR "Sclerosing Agents" OR D26.776.708.822$ OR D27.505.954.411.700$ OR D27.505.954.578.822$ OR D27.720.752.822$)) AND (DB:("IBECS" OR "LILACS"))
| Sclerotherapy versus laser therapy for telangiectasias | ||||||
| Patient or population: people with telangiectasias and reticular veins in the lower limb Settings: secondary care, outpatient Intervention: sclerotherapy Comparison: laser therapy | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect | No of Participants | Quality of the evidence | Comments | |
| Assumed risk | Corresponding risk | |||||
| Sclerotherapy | Laser therapy | |||||
| Clinically or photographically assessed resolution or improvement (or both) [range of scale or scale description] [follow up] | [value] per 1000 | [value] per 1000 | RR [value] ([value] to [value]) | [value] | ⊕⊝⊝⊝ ⊕⊕⊝⊝ ⊕⊕⊕⊝ ⊕⊕⊕⊕ | |
| Adverse events (including hyperpigmentation, bruising, anaphylaxis, necrosis of the skin) [range of scale or scale description] [follow up] | [value] per 1000 | [value] per 1000 | RR [value] ([value] to [value]) | [value] | ⊕⊝⊝⊝ ⊕⊕⊝⊝ ⊕⊕⊕⊝ ⊕⊕⊕⊕ | |
| Pain during procedure and post procedure [range of scale or scale description] [follow‐up] | The mean pain score ranged across control groups from | The mean pain score in the intervention groups was | [value] | ⊕⊝⊝⊝ ⊕⊕⊝⊝ ⊕⊕⊕⊝ ⊕⊕⊕⊕ | ||
| Recurrence [follow‐up] | [value] per 1000 | [value] per 1000 | RR [value] ([value] to [value]) | [value] | ⊕⊝⊝⊝ ⊕⊕⊝⊝ ⊕⊕⊕⊝ ⊕⊕⊕⊕ | |
| Time to resolution [range of scale or scale description] [follow‐up] | The mean time ranged across control groups from | The mean time in the intervention groups was | [value] | ⊕⊝⊝⊝ ⊕⊕⊝⊝ ⊕⊕⊕⊝ ⊕⊕⊕⊕ | ||
| Quality of life [range of scale or scale description] [follow‐up] | The mean quality of life score ranged across control groups from | The mean quality of life score in the intervention groups was | [value] | ⊕⊝⊝⊝ ⊕⊕⊝⊝ ⊕⊕⊕⊝ ⊕⊕⊕⊕ | ||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). | ||||||
| GRADE Working Group grades of evidence | ||||||
